Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus

Overview of attention for article published in Frontiers in immunology, August 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

So far, Altmetric has seen 22 X posts from 21 X users, with an upper bound of 66,474 followers.

RT @joraltron: 🔴📰Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus http…

RT @joraltron: 🔴📰Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus http…

RT @abdelhamed012: Frontiers | Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus eryt…

RT @joraltron: 🔴📰Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus http…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 18 additional X posts.